

Circassia's allergen immunotherapies to generate potential revenue of £1.3bn | Allergies, 8-9 July 2015, London, UK

SMi's 2nd annual Allergies conference, taking place on 8-9 July 2015 in London, will chart the pathways to the development of novel allergy therapeutics.

LONDON, ENGLAND, UNITED KINGDOM, June 22, 2015

/EINPresswire.com/ -- Circassia is working on four main treatments for [allergies](#) caused by house dust mites, grass, ragweed pollen and cat fur. The latter treatment, Cat-SPIRE, is due to report phase III clinical trial results in the first half of 2016. If successful, analysts forecast they could rake in annual sales of £1.3bn. The treatments were developed by researchers at Imperial College London and acquired by Circassia in 2006 when the firm was founded.

(Source: 'Cat allergy treatment could net billions for UK pharma Circassia', 26 Feb

2015, The Guardian)



Against this backdrop, we are delighted to announce that Circassia's Vice President R&D, Rod Hafner, will be presenting on Day 1 of SMi's 2nd annual Allergies conference on Challenges in the development of [allergen immunotherapies](#). Unique insight will be provided on the following areas:

- An introduction into the current situation in allergen immunotherapies
- Identification of key challenges and opportunities in the field
- Synthetic Peptide Immuno-Regulatory Epitopes: a new class of compounds

Additionally, Imperial College London's Professor of Respiratory Immunology, Clare Lloyd, will be leading a presentation titled Alternaria-derived serine protease: a novel pathway for asthma exacerbations mapped. Topics to be discussed include:

- Discussing the pathway involved in severe asthma exacerbations
- Providing a new target for therapeutics

SMi's 2nd annual Allergies conference, taking place on 8-9 July 2015 in London, will detail the latest cutting-edge developments in the field and the provide guidance on the direction allergy therapeutics

is heading with case study driven presentations from innovators such as MedImmune, Circassia, Allergy Therapeutics, HAL Allergies and many more.

[Speaker Panel](#) includes:

- Ian Strickland, Research Scientist, MedImmune
- Rod Hafner, Senior Vice President R&D, Circassia
- Tim Higenbottam, R&D Director, Allergy Therapeutics
- Diderik Boot, Medical Director, HAL Allergies
- Pierre-Henri Benhamou, CEO, DBV Technologies
- Juan Gispert, Senior Medical Director, European Head Allergy, Respiratory, Infectious Diseases and Vaccines, Quintiles
- Anne Marie Salapatek, President & Chief Scientific Officer, Inflamax Research, Inc.
- Tracy Hussell, Centre Director MCCIR, Manchester University
- Adam Chaker, Munich Allergy Research Centre, Klinikum rechts der Isar, Technische Universität München

To view the full speaker line-up and complete conference programme, visit <http://www.allergies-event.com/einpresswire>

Plus, don't miss the two interactive pre-conference workshops on:

A: Tear Biomarkers for Ocular Allergy

Led by: Dr Virginina Calder, Senior Lecturer, ORBIT, Institute of Ophthalmology, UCL

B: Improving probability of success in allergy clinical trials

Led by: Dr Juan Gispert, European Head Allergy, Respiratory, Infectious Diseases, Vaccines Medical Science & Strategy and Vivienne McDonald, Director, Site and Patient Networks, Site and Patient Networks, Quintiles

Vinh Trinh

SMi Group

+442078276140

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.